A Two-Part Phase 2/ 3 Multicentre, Double-Blind, Randomized, Placebo Controlled Study of Varlitinib Plus mFOLFOX6 Verses Placebo Plus mFOLFOX6 In Subjects With HER1/ HER2 Co Expressing Advanced or Metastatic Gastric Cancer Without Prior Exposure to Systemic Therapy
Phase of Trial: Phase II/III
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Varlitinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 31 Aug 2017 According to an ASLAN Pharmaceuticals media release, first patient has been enrolled in the study.
- 31 Aug 2017 Status changed from not yet recruiting to recruiting, according to an ASLAN Pharmaceuticals media release.
- 09 Jun 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.